The Patent Finder

Antibody-Drug-Conjugate and Its Use for the Treatment of Cancer

Pierre Fabre Medicament

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 5 of these applications claim priority to application PCT/EP2015/059052, filed Apr 27, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 10,314,921Antibody-Drug-Conjugate and Its Use for the Treatment of Cancer
In force
 · High confidence
UsedRemaining
Pierre Fabre MedicamentIn forceHigh confidence
US 10,912,841Antibody-Drug-Conjugate and Its Use for the Treatment of Cancer
In force
 · High confidence
Pierre Fabre MedicamentIn forceHigh confidence
US 11,219,693Antibody-Drug-Conjugate and Its Use for the Treatment of Cancer
In force
 · Medium confidence
Pierre Fabre MedicamentIn forceMedium confidence
US 11,517,625Antibody-Drug-Conjugate and Its Use for the Treatment of Cancer
In force
 · High confidence
Pierre Fabre MedicamentIn forceHigh confidence
US 11,918,656Antibody-Drug-Conjugate and Its Use for the Treatment of Cancer
In force
 · High confidence
Pierre Fabre MedicamentIn forceHigh confidence
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited